All articles tagged with #vaccine trial
The Jacksonville Center for Clinical Research is seeking participants for Phase 2 trials of a new oral COVID-19 vaccine developed by Vaxart. The pill-based vaccine, which is room-temperature stable, aims to reduce viral shedding and is being tested for effectiveness against the FLirt-variant of Omicron. The trial will last one year, and interested individuals can contact the center to participate.
The University of Cincinnati Cancer Center is conducting a Phase 2 clinical trial for a personalized vaccine to treat pancreatic cancer, utilizing mRNA technology similar to that used for COVID-19 vaccines. After surgery, a personalized vaccine is developed and administered to patients, followed by standard chemotherapy and booster shots. The trial aims to enroll 260 patients globally, with minimal side effects reported in Phase 1 and promising results, including an 25% cure rate. Researchers believe this vaccine could be a game changer in pancreatic cancer treatment.
The University of Cincinnati Cancer Center has initiated enrollment for a Phase 2 clinical trial testing a vaccine for pancreatic cancer, utilizing mRNA technology similar to that used in COVID-19 vaccines. The trial aims to enroll 260 patients globally and offers a personalized vaccine targeting each individual's cancer specifically. Patients receive injections of the vaccine after surgery and chemotherapy, with minimal reported side effects. The trial has shown promising results, with 25% of patients in the Phase 1 trial being completely cured of their cancer. For more information on the trial, individuals can call 513-584-7698 or email [email protected].
NBC News correspondent Kristen Dahlgren left journalism to launch the Pink Eraser Project, aiming to accelerate the development of a breast cancer vaccine. Dr. Nora Disis' vaccine trial at the University of Washington's Cancer Vaccine Institute has shown promising results, with breast cancer survivor Jennifer Brouwer participating in the Phase 2 trial. The vaccine aims to teach the body to identify and destroy cancer stem cells using the immune system. The Pink Eraser Project seeks to streamline effective studies and bring together leading researchers to eradicate breast cancer as a fatal disease. Brouwer, hopeful for a medical breakthrough, encourages women to consider participating in clinical trials and not to dismiss the idea due to misconceptions.
The University of Oxford has initiated the first human trial for a vaccine against the Nipah virus, a zoonotic pathogen with a mortality rate of up to 75%. The ChAdOx1 NipahB vaccine is being tested on 51 volunteers to evaluate its safety and immune responses. With no approved vaccines or treatments for Nipah virus, this trial marks a significant step in pandemic preparedness, and further research is expected to follow in Nipah virus-affected countries.
The PrEPVacc HIV vaccine trial, considered the "last roll of the dice" in the search for an effective HIV vaccine, has been halted due to disappointing results. The trial, led by African researchers with support from European scientists, was testing two experimental vaccines alongside a new form of oral pre-exposure prophylaxis (PrEP). While there are no safety concerns, the vaccine component was found to be ineffective in preventing HIV. This setback is a significant blow to the medical community, which has been searching for an HIV vaccine for 36 years. The trial's failure highlights the urgent need for new vaccine approaches and technology.
The first trial in Africa testing two combination vaccines to prevent HIV has been halted after researchers determined that the vaccines were not effective in reducing the risk of acquiring HIV. The trial, which involved 1,500 participants in Uganda, Tanzania, and South Africa, was stopped after an interim review of progress. The final results are expected to be released in late 2024. This setback means that there are currently no HIV vaccines being tested for efficacy anywhere in the world. Despite the disappointing results, researchers remain optimistic about the development of an effective HIV vaccine in the future.
Pfizer and BioNTech have announced that their flu-COVID vaccine has generated a strong immune response against strains of both viruses in an early- to mid-stage trial. The companies plan to proceed with a late-stage trial in the coming months. The vaccine has the potential to simplify immunization practices by addressing two respiratory diseases with a single injection. The trial data showed robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains.
Pfizer and BioNTech announced that their flu-COVID vaccine generated a strong immune response against strains of both viruses in an early- to mid-stage trial. The vaccine candidates were compared to a licensed influenza vaccine and the companies' updated COVID-19 vaccine, and the data showed robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains. The companies plan to proceed with a late-stage trial in the coming months, with the potential to simplify immunization practices by addressing two respiratory diseases with a single injection.
The University of Vermont Medical Center and UVM's Larner College of Medicine are recruiting participants for a clinical trial of a Pfizer vaccine to protect against Lyme disease. The trial, called VALOR, will take place over 30 months and involve at least seven clinic visits and several blood draws. Lyme disease, caused by tick-borne bacteria, is increasingly present in Vermont, with over half of all ticks collected in the state in 2020 found to be infected. Currently, there are no approved vaccines for Lyme disease in humans, but Pfizer's Phase 2 trial showed promising results, and the Phase 3 trial aims to determine the vaccine's effectiveness.
Pfizer expects to enroll fewer participants than originally estimated for the Phase III trial of Valneva's Lyme disease vaccine candidate, known as the VALOR study. The trial will now enroll approximately 9,000 people aged five or older, instead of the initial estimate of 18,000 participants.
A Scottish couple rushed their 3-year-old daughter to the hospital after she exhibited odd symptoms, only to find out she had Stage 4 high risk neuroblastoma. The toddler has completed six rounds of chemotherapy and will undergo a higher dose of chemo and a stem cell transplant as part of her 18-month treatment. Her family is fundraising to send her to Memorial Sloan Kettering Cancer Center in NYC for a vaccine trial to stop the cancer from returning. Without the treatment, Ava is more likely to relapse, reducing her chances of survival.
A vaccine trial for melanoma appears to reduce the recurrence of skin cancer, according to a study published in the journal Nature Medicine. The vaccine, which uses immunotherapy to stimulate the immune system to attack cancer cells, was tested on 120 patients who had undergone surgery to remove melanoma. The trial found that the vaccine reduced the risk of recurrence by 30% compared to a control group. The researchers hope that the vaccine could eventually be used to prevent the spread of melanoma to other parts of the body.
Cincinnati Children's Hospital Medical Center is conducting a clinical trial on a vaccine for shigellosis, a diarrheal disease caused by shigella bacteria. The trial involves taking an oral vaccine and being exposed to shigella to determine its effectiveness. The National Institutes of Health is sponsoring the vaccine clinical trials at Cincinnati Children's and Emory University Hospital in Atlanta. The U.S. Army is interested in providing troops an effective vaccine, and such a vaccine would save many children around the world who are at high risk and can die from it.